Ryu Kariyawasam-Chavez, Content Associate

Psilocybin-assisted psychotherapy significantly increased cocaine abstinence rates and reduced relapse risk in patients with cocaine use disorder.

Effective real-world management of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) is critical to safely delivering CAR T-cell therapies and bispecific antibodies.

Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on strategies to improve OTC counseling through clear and accessible communication, considerations for high-risk patient populations such as older adults and those with chronic conditions, and emerging trends shaping the future of OTC care and the expanding role of pharmacy technicians in patient education.

The ACCESS trial found that expanding hematopoietic cell transplant eligibility through mismatched unrelated donors increased racial, ethnic, and socioeconomic diversity among recipients.

Emerging synthetic opioids known as orphines are entering the illicit drug supply with extreme potency and detection challenges.

Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on how pharmacy technicians can recognize when patients should be referred to a pharmacist or physician instead of self-treating with OTC products, and how to help patients avoid risks associated with combination products such as duplicate ingredients.

Bispecific antibodies show strong efficacy in relapsed/refractory lymphoma and early promise in frontline combination settings.

Data from a large New York State analysis found that sickle cell disease hospitalizations are becoming more severe over time, with significant regional disparities in outcomes, costs, and access to specialized care.

Renee’ Acosta, RPh, MS, discusses recent developments in the OTC market and key considerations pharmacy staff should prioritize when guiding patients in selecting appropriate over-the-counter therapies.

Phase 3 MagnetisMM-5 trial data demonstrated that Elrexfio (elranatamab) significantly improved progression-free survival compared with standard-of-care therapy in patients with relapsed or refractory multiple myeloma.

Emerging data regarding newly diagnosed AML found that the Endothelial Activation and Stress Index independently predicts early mortality and ICU admission during intensive induction chemotherapy.

Harm reduction–based counseling frameworks for cannabis use during pregnancy and lactation can improve patient engagement, disclosure, and safety, with pharmacists playing a key role in implementation.

Symptom-based dosing reduced time to medical readiness for discharge compared with scheduled opioid, without increasing short-term safety risks.

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.

Cannabis use is common among patients receiving medications for opioid use disorder and is associated with higher rates of anxiety and other comorbid symptoms.

The emerging data suggest a potential adjunctive strategy to target microbial drivers of head and neck squamous cell carcinoma.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.

Emerging data found that initiating low-dose aspirin at giant cell arteritis diagnosis was associated with reduced 1-year major cardiovascular events but an increased risk of major bleeding.

Pharmacy Times interviews Robert R. Jeng, MD, on how the gut microbiome may influence CAR T-cell therapy response, toxicity, and persistence, as well as the challenges and future potential of microbiome-based interventions in improving patient outcomes.

Pharmacy Times interviews Kamel Lahouel, PhD, and Cristian Tomasetti, PhD, on the challenges of predicting MHC class II peptide binding and how combining structural and sequence-based models can improve accuracy while addressing key limitations.

Pharmacy Times interviews Lorin Fisher, PhD, BCACP, on her presentation, “Gabapentin for Pain Management: Well Done or Overdone?,” presented at the SPPCP conference. Fisher discusses the evolving role of gabapentin in pain care, highlighting where evidence supports its use, where it may be overprescribed, and key considerations for pharmacists in optimizing safe and appropriate therapy.

Pharmacy Times interviewed Kimlin Ashing and Narissa Nonzee about their work examining how housing status, race, and ethnicity drive cancer screening disparities.

Enrique Velazquez Villarreal, MD, PhD, used a conversational AI platform to unify microbiome, genomic, clinical, and social determinants of health data for colorectal cancer research.

Research presented at the American Association for Cancer Research Annual Meeting shows personalized mRNA vaccine immunotherapy targets pancreatic cancer tumor neoantigens, sparking durable T-cell responses and boosting survival in a phase 1 clinical trial.

Emerging data find buprenorphine in pregnancy matches methadone for autism and ADHD risk, supporting safer opioid MOUD access in pharmacy care.

Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.

Gwen Nichols shares her dream of changing the landscape of pediatric cancer research and care.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.